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Abstract
Objective: Chronic periaortitis (CP) is a rare disease that is characterised by fibro-inflammatory tissue surrounding the
abdominal aorta and has both non-aneurysmal (idiopathic retroperitoneal fibrosis [IRF]) and aneurysmal forms
(inflammatory abdominal aortic aneurysm [IAAA]). We investigated whether toll-like receptor 4 (TLR-4) and vascular
endothelial growth factor (VEGF) polymorphisms were associated with susceptibility to, and the clinical features of CP.
Methods: One hundred and two CP patients and 200 healthy controls were molecularly genotyped for TLR-4 gene
polymorphism (+896 A/G) (rs4986790), VEGF mutations +936 C/T (rs3025039) and 2634 C/G (rs2010963), and an 18 base
pair (bp) insertion/deletion (I/D) polymorphism at 22549 of the VEGF promoter region. The patients were grouped on the
basis of the type of CP (IRF or IAAA), and the presence or absence of established atherosclerotic disease (ischemic heart
disease, cerebrovascular disease, and peripheral arterial disease).
Results: There were no significant differences in the distribution of the studied polymorphisms between the patients and
controls. However, carriage of the +936 T allele was significantly more frequent in the patients with IRF than in those with
IAAA (26.5% vs 5.3%; p = 0.046; OR 6.49 [95% CI 0.82–51.54]). There were significantly more carriers of the I allele among the
patients with ureteral obstruction (83.8% vs 58.8%; p = 0.006; OR 3.63 [95% CI 1.42–9.28]) and those who received
conservative treatment (48.5% vs 23.5%; p = 0.015; OR 3.06 [95% CI 1.22–7.721]) than among those without, and II
homozygosity was significantly more frequent in the patients with deep vein thrombosis than in those without (30.4% vs
11.7%, p = 0.031; OR 3.31 [95% CI 1.07–10.21]).
Conclusion: The VEGF +936 C/T polymorphism may be associated with an increased risk of developing the non-aneurysmal
IRF form of CP. Carriers of the I allele and II homozygosity are respectively at increased risk of developing ureteral
obstruction and deep vein thrombosis.
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Introduction
Chronic periaortitis (CP) is an immune-mediated disease
characterised by a fibro-inflammatory reaction arising from the
adventitia of the abdominal aorta and common iliac arteries that
may spread into the retro-peritoneum [1,2]. It has non-aneurysmal
and aneurysmal forms, which are traditionally and respectively
known as idiopathic retroperitoneal fibrosis (IRF) and inflamma-
tory abdominal aortic aneurysms (IAAA). As these conditions have
common clinical and histopathological findings, they are consid-
ered to be the opposite ends of the same disease spectrum [1].
The pathogenesis of CP is still unclear. Earlier studies suggested
that it might arise as an exaggerated localised inflammatory
reaction to severe atherosclerosis plaques in the abdominal aorta.
However, the absence of advanced atherosclerosis in some patients
and, more importantly, the presence of constitutional symptoms,
autoantibodies, and markedly increased acute-phase reactant
levels, together with the frequent association with other autoim-
mune conditions, suggest a systemic immune-mediated process
rather than a local reaction [1–3]. This hypothesis is further
supported by the association between CP and HLA-DRB1*03, an
allele linked to various immune-mediated diseases [4], and
between the CC chemokine receptor 5 (CCR5) D32 polymor-
phism and the aneurysmal form of CP in patients without
atherosclerotic disease [5], as well as by the marked adventitial
lymphoplasmacytic infiltration of the aorta that is typical of CP [6–
8].
Studies of aortic biopsy specimens taken from in CP patients
have revealed the expression of gene transcripts consistent with
lymphocytic activation (interferon-c, interleukin(IL)-1a, IL-2 and
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IL-4), which supports the concept that CP may originate as an
active inflammatory condition of the aortic wall [9].
Toll-like receptor 4 (TLR-4) is an important pathogen
recognition receptor that plays a major role in innate and adaptive
immune responses by binding to pathogens, microbial toxins, or
endogen ligands such as heat-shock proteins, modified lipids and
others [10,11].
It has been shown that the engagement of TLRs induces T cell
activation, as seen in immune-mediated disorders [11]. As TLR-4
and TLR-5 ligands trigger vascular dendritic cells (DCs) and
induce T cell recruitment and activation in patients with large
vessel vasculitides [12], TLR-4 may also play a key role in the
pathogenesis of CP, which is characterised by inflammatory
involvement of the abdominal aorta and the origin of the epi-
aortic arteries, as well as of other large arteries such as the
gastrointestinal vessels [1,2,13]. Recently, two co-segregating
single nucleotide polymorphisms (SNPs) within the gene encoding
TLR-4 (Asp299Gly and Thr399Ile) have been characterised [14]
and studied in various inflammatory and infectious conditions
[15–27], and it is known that they impair the efficacy of
lipopolysaccharide (LPS)-induced signalling and its capacity to
elicit inflammation [14].
Vascular endothelial growth factor (VEGF) may also be
involved in the pathophysiology of CP because it is not only a
potent angiogenic factor, but also acts as a pro-inflammatory
cytokine by increasing endothelial permeability and inducing the
chemokines and adhesion molecules that bind leukocytes to
endothelial cells [28]. As a wide range of adhesion molecules have
been detected in the aortic adventitia of patients with CP [29],
VEGF seems to be an attractive candidate as a CP susceptibility
gene. VEGF production may be partially subject to genetic
control. It has been found that two VEGF gene mutations, +936
C/T in the 39- UTR [30] and 2634 C/G occurring in 59-UTR
(erroneously described as a +405 polymorphism in a previous
study) [31], regulate plasma VEGF levels, and an 18 base pair (bp)
insertion/deletion (I/D) polymorphism at position 22549 of the
VEGF promoter region has also been described [32]. There is
evidence that these three functional polymorphisms are associated
with immune-mediated conditions, particularly vasculitides [33–
38].
In the light of the above, the aim of this study was to investigate
the potential associations of the two TLR-4 and three VEGF
polymorphisms with CP susceptibility and disease expression. In
addition, we explored whether the presence of an established




The study involved 102 CP patients consecutively recruited at
two Italian referral centres (Milan and Parma) over a period of ten
years. The diagnosis of CP was confirmed by means of computed
tomography (CT) or magnetic resonance imaging (MRI) showing
a homogeneously attenuated retroperitoneal mass of soft tissue
density surrounding the abdominal aorta and/or the iliac arteries,
without aortic displacement or bone destruction. None of the
patients had any clinical or laboratory evidence of chronic
infections, tumours or trauma, or a history of major abdominal
surgery and/or radiotherapy, and none of them was taking any
medication known to induce CP.
The control group consisted of 200 unrelated, healthy, age- and
gender-matched blood donors (60% males) with a mean age of
57613 years.
All of the study subjects were Caucasians who had been resident
in Italy for at least one generation, and there were no ethnic
differences between the patients and controls. The study was
approved by the Ethic Committees ‘‘Provinciale of Reggio
Emilia’’, and written informed consent was obtained from the
patients and controls before study entry.
All of the medical records of the patients were reviewed, and the
data of all of the confirmed cases were recorded using a
standardised data collection form that included clinical symptoms
at presentation and during follow-up, co-morbidities, laboratory
investigations, detailed radiological findings (CT, MRI, positron
emission tomography [PET] scans, and conventional angiograms),
pathological specimens (retroperitoneal biopsy), treatment regi-
mens, response to treatment, the number of relapses, surgical
interventions, and causes of death.
If baseline creatinine (Cr) levels were available, acute renal
failure was defined as a rapid increase of .50% or .1 mg/dL in
serum Cr levels in patients with known renal insufficiency;
otherwise, it was defined as an impaired renal function (serum
Cr .1.4 mg/dl) that proved to be reversible after the obstructive
uropathy had been corrected (e.g. by means of ureteral stents).
Information concerning established ischemic heart disease,
cerebrovascular accidents and peripheral arterial disease (PAD)
preceding the onset of CP was obtained from in- and outpatient
medical records, as well as by means of patient interviews
whenever required. Ischemic heart disease was diagnosed if the
patient had a history of acute myocardial infarction (AMI), silent
AMI, revascularisation procedures, or angina pectoris. Silent AMI
was defined as a documented characteristic electrocardiogram
(ECG) or a physician’s recorded diagnosis in patients with no
documented history of AMI. A diagnosis of cerebrovascular
disease was defined as a clearly documented history of stroke
confirmed by CT or MRI, and/or a transient ischemic attack. A
diagnosis of PAD was defined as the presence of at least one of the
following: symptoms of intermittent lower limb claudication or
ischemic pain at rest in the absence of pedal and posterior artery
pulses, or bruits over the femoral arteries; previous peripheral
artery surgery, endovascular interventional procedures; or lower
extremity amputation due to PAD.
The erythrocyte sedimentation rate (ESR) was determined using
Westergren’s method (upper normal limit 30 mm/1st h), and C-
reactive protein (CRP) levels were measured by means of
nephelometry (NA latex CRP kit, Behringwerke, Marburg,
Germany; upper normal limit 5 mg/L).
Molecular analysis of TLR-4 polymorphisms
DNA was obtained from whole blood using the standard
phenol/chloroform extraction method [39]. Polymerase chain
reaction (PCR) was used to amplify two small regions of the TLR-4
gene [40]: a 248 bp fragment containing the rs4986790
Ex4+636A.G Asp299Gly polymorphism (forward primer
59GATTAGCATACTTAGACTACTACCTCCATG39 and re-
verse primer 59GATCAACTTCTGAAAAAAGCATTCC-
CAC39), and a 405 bp fragment containing the rs4986791
Ex4+936C.T Ile399Thr polymorphism (forward primer 59GAT-
TAGCATACTTAGACTACTACCTCCATG39 and reverse
primer 59GATCAACTTCTGAAAAAAGCATTCCCAC39).
The two forward primers have an altered nucleotide that is useful
for creating a restriction site for Ncol (the first) and Hinfl
endonucleases (the second). The amplifications were performed in
a 25 ul reaction mixture containing 100 uM of each dNTP,
20 pmol of each primer, and 1 unit of Taq polymerase.
The amplification profile for the 248 bp amplicon was initial
denaturation at 95uC for 2 min, followed by 35 cycles (30 sec at
TLR-4 and VEGF Polymorphisms in CP
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94uC, 30 sec at 58uC, and 30 sec at 72uC), with a final extension
at 72uC for 3 min. The amplification profile for the 405 bp
amplicon was initial denaturation at 95uC for 2 min, followed by
35 cycles (30 sec at 94uC, 30 sec at 66uC, and 30 sec at 72uC),
with a final extension at 72uC for 3 min.
Ten microlitres of the PCR products were digested by Ncol and
Hinfl restriction endonucleases, which can reveal the alleles
because Ncol cuts the 248 bp amplicon only if allele A is replaced
by G, and Hinfl cuts the 405 bp amplicon only if C is replaced by
T. The different genotypes were revealed by means of electro-
phoretic analysis of the digested PCR products in 2.5% agarose gel
stained with ethidium bromide (0.5 ug/mL).
Molecular analysis of VEGF polymorphisms
DNA was extracted from the whole blood of the healthy
controls and CP patients using a standard phenol, chloroform and
isoamyl alcohol method [39], and VEGF was genotyped by PCR
followed by restriction analysis.
The primers were 59ATTTATTTTTGCTTGCCATT39 and
59GTCTGTCTGTCTGTCCGTCA39 for the VEGF +634
polymorphism [31]; 59AAGGAAGAGGAGACTCTGCG39 and
59TATGTGGGTGGGTGTGTCTA39 for the VEGF +939
polymorphism [30]; and 59CCTGGAGCGTTTTGGTTAAA39
and 59ATATAGGAAGCAGCTTGGAA39 for the 18 bp I/D
polymorphism [32]
PCR was carried out using a PE 9600 thermal cycler (Perkin
Elmer Cetus, Norwalk, CT, USA) and a 50 mL reaction volume
containing 100 ng template DNA, 50 mM KCl, 10 mM Tris-
HCl, 0.1% Triton X-100, 200 mM each of dATP, dCTP, dGTP
and dTTP (Amersham Pharmacia Biotech, Uppsala, Sweden),
2.5 mM MgCl2, 0.5 mM of each primer, and 1 U Taq DNA
Polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). Following
an initial denaturation step (2 min at 95uC), the samples
underwent 35 cycles consisting of 30 sec at 95uC, 30 sec at
60uC (VEGF +634) or 30 sec at 67uC (VEGF +936) or 30 sec at
55uC (18 bp I/D), and 30 sec at 72uC, followed by a final
extension at 72uC for 5 min. The +634 polymorphism PCR
products were digested using restriction endonuclease Bsm FI
(New England Biolabs, Beverly, MA, USA), and the restriction
fragments were analysed on 2% agarose gel. The 304 bp C allele
remained uncut, whereas the G allele was cut into two fragments
of 193 bp and 111 bp. The +936 polymorphism PCR products
were digested using restriction endonuclease Nla III (New England
Biolabs, Beverly, MA, USA) and the restriction fragments were
analysed on 2% agarose gel. The 208 bp C allele remained uncut,
whereas the T allele was cut into two fragments of 122 bp and
86 bp. The 18 bp I/D polymorphism PCR products were
visualised on 2% agarose gel, which revealed two fragments: a
234 bp I allele with an 18 bp insertion, and a 216 bp D allele
without insertion.
Measurement of serum VEGF concentrations
Serum was obtained at the time of diagnosis from 17 untreated
CP patients included in the genetic study, and was stored at
280uC until use. All of the patients were recruited by the
Nephrology Unit of Parma University Hospital, and they all had
IRF; no serum samples from patients with IAAA were available.
The control group consisted of 11 age- and gender-matched
healthy subjects. Serum VEGF levels were measured using the
Bio-Rad Luminex assay (Bio-Rad Laboratories, Life Science
Group, Hercules, CA, USA). All of the samples and standards
were analysed in duplicate using a Luminex 100 for cytokine
detection and Bio-Rad Manager software, version 4.0 (Bio-Rad
Laboratories, Life Science Group, Hercules, CA, USA).
Statistical analysis
The data were statistically analysed using the SPSS statistical
package (SPSS Inc., Chicago, IL, USA; version 18.0, 2009). The
frequencies of the alleles and genotypes in the patients and controls
were compared using the chi-squared test. Fisher’s exact test was
used when the minimum expected value was ,5. Odds ratios
(ORs) were calculated together with their 95% confidence
intervals (95% CI). Asymptotic look-up distribution with continu-
ity correction was used to determine the p values. The cases and
controls were tested for conformity to the Hardy-Weinberg
equilibrium using a 262 chi-square test between observed and
expected numbers [41]. The differences in serum VEGF levels
were assessed using the Mann-Whitney test.
Results
Table 1 shows the demographic and clinical characteristics of
the 102 CP patients: 83 had IRF and 19 IAAA. Twenty-six
(25.7%) of the 101 patients for whom relevant data were available
had established atherosclerotic disease diagnosed at baseline or
during follow-up. The control and case populations, and the IAAA
and IRF subgroups, were tested for Hardy-Weinberg equilibrium:
genotype frequencies did not reject Hardy-Weinberg equilibrium
in any case.
Table 2 shows the allele and genotype frequencies of the of
TLR-4 Asp299Gly polymorphism in the patients and controls.
Eight (8.1%) of the 102 CP patients and 17 (8.5%) of the 200
controls were heterozygous for the Asp299Gly TLR-4 allele; there
were no homozygous subjects in either group. All of the the eight
patients and 17 controls showed co-segregation of the Thr399Ile
polymorphism, whereas none of the patients or controls had an
isolated Asp299Gly polymorphism. The distribution of allele and
genotype frequencies was not significantly different between the
patients and controls.
Carriers of the G allele (G/A+G/G) were similarly represented
in the two groups. Stratification of the patients by IRF or IAAA
did not reveal any significant association with the TLR-4
Asp299Gly polymorphism in either group.
We also investigated the association of the TLR-4 Asp299Gly
polymorphism with CP, IRF, and IAA, after stratifying the study
subjects by the presence/absence of atherosclerotic disease. There
were no significant differences in allele frequencies between the
patients with or without atherosclerotic disease and the healthy
controls (data not shown).
The associations between the TLR-4 Asp299Gly polymorphism
and the clinical manifestations of CP shown in Table 1 were
evaluated by comparing the frequencies of the clinical manifes-
tations between the G allele carriers and non-carries; no significant
differences were found (data not shown).
Table 3 shows the allele and genotype frequencies of the three
VEGF polymorphisms in the patients and controls. There were no
statistically significant differences in allele frequencies or genotype
distribution. The carriers of the I allele (II or ID), 2C634 allele
(C634/C634 or C634/G634), and +T936 allele (T936/T936 or
T936/C936) were similarly represented in the patient and control
groups.
Comparing the distribution of allele frequencies of the three
VEGF polymorphisms among the IAAA and IRF patients, the
+936T allele was significantly more frequent in the patients with
IRF (26.5% vs 5.3%; p = 0.046; OR 6.49 [95% CI 0.82–51.54]).
We also investigated the association of the three VEGF
polymorphisms with CP, IRF, and IAAA, after stratifying the
patients by the presence/absence of atherosclerotic disease. There
were no significant differences in allele frequencies between the
TLR-4 and VEGF Polymorphisms in CP
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Table 1. Demographic and clinical characteristics of the 102 patients with chronic periaortitis*&.
Mean age at disease onset 6 SD (years) 58612
Males/females 65.7/34.3
Idiopathic retroperitoneal fibrosis 83/102 (81.4)




Atypical localisation 8/102 (7.8)
Thoracic vessel or mediastinal involvement 22/58 (37.9)
Presence of atherosclerotic disease (at diagnosis or during follow-up)** 26/101 (25.7)
Systemic symptoms and/or signs1 76/100 (76.0)
Abdominal/lumbar pain 85/101 (84.2)
Constipation 29/99 (29.3)
Testicular symptoms 39/65 (60.0)
Deep vein thrombosis 16/100 (16.0)
Ureteral obstruction 77/102 (75.5)
Unilateral 28/102 (27.5)
Bilateral 50/102 (49.0)
Acute renal failure 49/102 (48.0)
Conservative treatment (stents, nephrostomies) 41/102 (40.2)
Surgical ureterolysis 28/102 (27.5)
Retroperitoneal biopsy 55/101 (54.5)
Associated autoimmune/inflammatory diseases 41/95 (43.2)
Autoimmune thyroiditis 20/88 (22.7)
ANA positivity 32/97 (33.0)
Other positive autoantibodies 46/96 (47.9)
Mean duration of follow-up 6 SD (months) 42.5638.7
Mean ESR at diagnosis 6 SD (mm/hour) 68632
Mean CRP level at diagnosis 6 SD (mg/L) 41.4643.6
*Values indicate the percentage of patients unless otherwise indicated.
&Some characteristics were not available for all 102 patients.
**Atherosclerotic disease: the presence of coronary artery disease, cerebrovascular disease or peripheral arterial disease.
1Fever, anorexia, and weight loss.
ANA = antinuclear antibodies; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.
doi:10.1371/journal.pone.0062330.t001
Table 2. Alleles, genotypes and carriage rate frequencies (%) of the Toll-like receptor (TLR) 4 polymorphism Asp299Gly in patients
with chronic periaortitis and control subjects*.
Chronic periaortitis (n = 99) Controls (n = 200) P OR (95% CI)
Alleles
G 8/198 (4.0) 17/400 (4.3) 0.904 0.95 (0.40–2.24)
A 190/198 (96.0) 383/400 (95.8)
Genotype
G/G 0/99 (0.0) 0/200 (0.0)
G/A 8/99 (8.1) 17/200 (8.5) 0.902
A/A 91/99 (91.9) 183/200 (91.5)
Carriage rate
G/A+G/G 8/99 (8.1) 17/200 (8.5) 0.902 0.94 (0.39–2.27)
A/A 91/99 (91.9) 183/200 (91.5)
*Values are the number/total number examined (%).
OR = odds ratio; 95% CI = 95% confidence interval.
doi:10.1371/journal.pone.0062330.t002
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patients with or without atherosclerotic disease and the healthy
controls (data not shown).
The associations between the three VEGF polymorphisms and
the clinical manifestations of CP as defined in Table 1 were
evaluated by comparing the frequencies of the clinical manifes-
tations between the carriers and non-carriers of the I, 2C634 and
+T936 alleles. The carriers of the I allele (II+ID) were significantly
more likely to have ureteral obstruction (83.8% vs 58.8%, p = 006;
OR 3.63 [95% CI 1.42–9.28]) and to receive conservative
treatment (48.5% vs 23.5%, p = 0.015; OR 3.06 [95% CI 1.22–
7.72]). The patients with deep vein thrombosis were more likely to
show II allele homozygosity than those without (30.4% vs 11.7%;
p = 0.031; OR 3.31 [95% CI 1.07–10.21] (Table 4).
Serum VEGF levels tended to be higher in the CP (IRF)
patients (median 393 pg/mL, range 26–1398 pg/mL) than in the
healthy controls (median 193 pg/mL, range 89–254 pg/mL), but
this difference was not statistically significant (P = 0.081) (Fig. 1).
Serum VEGF levels tended to be higher in the patients with the
wild-type +936 C/C genotype (median 454 pg/mL, range 44–
1398 pg/mL) than in those with the C/T genotype (median
194 pg/mL, range 26–363 pg/mL, p = 0.157), and were signifi-
cantly higher than the levels in the healthy controls (p = 0.037),
which were similar to those observed in the patients with the C/T
genotype (p = 0.948).
Discussion
We investigated whether polymorphisms of the TLR-4 and
VEGF genes might be linked to susceptibility to, and the clinical
manifestations of CP. TLRs play a role in many diseases, including
those considered to be autoimmune in nature [10,11]. In
particular, the inappropriate activation of TLR pathways by
endogenous or exogenous ligands may lead to the initiation and/
or perpetuation of autoimmune responses [10,11].
There is evidence that CP originates as a primary aortitis
leading to a fibro-inflammatory reaction in the adjacent periaortic
retroperitoneum. Histopathological findings demonstrate that
most of the thickening of the aortic wall in CP patients is due to
an enlargement of the adventitia caused by a marked inflamma-
tory reaction. Nodular aggregates of inflammatory cells are usually
centred around the adventitial vasa vasorum, which may show
signs of vasculitis with fibrinoid necrosis [7]. Similarly, a subset of
patients with giant cell arteritis (GCA) are characterised by
perivasculitis, with the inflammation being restricted to the vasa
vasorum, the periadventitial small vessels, or both [42]. Deng et al.
[12] have elegantly demonstrated that the ligands of TLR4 can
induce the activation and maturation of adventitial DCs in GCA
patients, and that this initiates the cascade of events that leads to
the recruitment and activation of T cells in the arterial adventitia
and subsequent vessel wall inflammation. The same authors also
showed that TLR4 and TLR5 induce distinct types of vasculitis in
Table 3. Alleles, genotypes and carriage rates frequencies (%) of VEGF I/D, 936 C/T, 634 C/G in patients and control subjects*.
Variable
Chronic periaortitis
(n = 102) Controls (n = 200) p OR (95% CI)
Alleles
I 92/204 (45.1) 162/400 (40.5) 0.279 1.21 (0.86–1.70)
D 112/204 (54.9) 238/400 (59.5)
T936 24/204 (11.8) 40/400 (10.0) 0.505 1.20 (0.70–2.05)
C936 180/204 (88.2) 360/400 (90.0)
C634 83/202 (41.1) 155/400 (38.8) 0.579 1.10 (0.78–1.56)
G634 119/202 (58.9) 245/400 (61.3)
Genotypes
II 24/102 (23.5) 48/200 (24.0)
ID 44/102 (43.1) 66/200 (33.0) 0.174
DD 34/102 (33.3) 86/200 (43.0)
T936/T936 1/102 (1.0) 3/200 (1.5)
T936/C936 22/102 (21.6) 34/200 (17.0) 0.596
C936/C936 79/102 (77.5) 163/200 (81.5)
C634/C634 12/101 (11.9) 27/200 (13.5)
C634/G634 59/101 (58.4) 101/200 (50.5) 0.425
G634/G634 30/101 (29.7) 72/200 (36.0)
Carriage rates
II+ID 68/102 (66.7) 114/200 (57.0) 0.104 1.51 (0.92–2.48)
DD 34/102 (33.3) 86/200 (43.0)
T936/T936+T936/C936 23/102 (22.5) 37/200 (18.5) 0.404 1.28 (0.71–2.30)
C936/C936 79/102 (77.5) 163/200 (81.5)
C634/C634+C634/G634 71/101 (70.3) 128/200 (64.0) 0.276 1.33 (0.79–2.23)
G634/G634 30/101 (29.7) 72/200 (36.0)
*Values are the number/total number examined (%).
OR = odds ratio; 95% CI = 95% confidence intervals.
doi:10.1371/journal.pone.0062330.t003
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GCA patients, with TLR4 ligands causing transmural panarteritis
and TLR5 ligands promoting adventitial perivasculitis [12]. It can
also be postulated that TLR4 or TLR5 may also play a key role in
CP. In particular, the inappropriate activation of TLR by
atherosclerotic plaque antigens or other endogenous or exogenous
ligands may activate DCs and trigger the marked adventitial
inflammatory reaction typical of CP.
In 2002, Arbour et al. [14] described two co-segregating
polymorphisms of the human TLR4 gene, Asp299Gly and
Thr399Ile. These two SNPs are characterised by an A/G
transition causing an aspartic acid/glycine substitution at amino
acid location Asp299Gly (rs4986790), and a C/T transition
causing a threonine/isoleucine switch at amino acid location
Thr399Ile (rs4986791). Both polymorphisms occur with an allelic
frequency of approximately 3–6% in Caucasians [18]. The allelic
frequency in our control population (4.3%) was similar to that
reported in a previous Italian study (7.2%) [43]. Furthermore, and
in line with the very rare occurrence of homozygous mutations, we
found no homozygous patients or controls.
Arbour et al. [14] were the first to investigate the functional
consequence of TLR4 polymorphisms, and found that subjects
with the Asp299Gly and/or Thr399Ile polymorphism had a
blunted response to inhaled LPS. Furthermore, in comparison
with wild-type TLR4, transfected cells with TLR4 polymorphisms
showed decreased NF-kB activity leading to reduced cytokine
production.
Since their identification, a series of studies have examined the
impact of these polymorphisms on the incidence and course of
inflammatory disorders, including vasculitides, with conflicting
results [15–27]. The first Spanish study showed that the frequency
of the TLR4 +896 G allele was significantly higher in patients with
biopsy-proven GCA than in controls [23], whereas a second
Spanish study [24] and an Italian [22] study did not confirm this
association. In an attempt to provide a more definitive conclusion,
a cumulative meta-analysis of the association of the TLR4 +896
A/G polymorphism with GCA susceptibility was made (which
included these three studies), and failed to find any association
[25].
Ours is the first study to examine TLR4 polymorphisms in CP
patients. Our findings in a large and ethnically homogeneous
Italian cohort indicate that these polymorphisms are not associated
with CP susceptibility or its clinical manifestations, which suggests
that they do not play an important role in the pathogenesis of CP.
Because of its angiogenic and pro-inflammatory activities,
VEGF may play a role in the inflammatory process involving
the aortic vasa vasorum and periaortic retroperitoneal vessels that
leads to the development of CP. It is capable of upregulating
endothelial adhesion molecules and chemokine expression, and
Ramshaw and Parums [29] have shown that the expression of
intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) closely correlate with the adven-
titial mononuclear infiltrate in CP patients. Mangieri et al. [44]
have recently observed that serum levels of eotaxin/chemokine (C-
C motif) ligand 11 (CCL11) are significantly higher in CP patients
than in healthy controls, and that it is also highly expressed by
mononuclear cells in the inflammatory infiltrate of retroperitoneal
biopsies obtained from CP patients. Similarly, Boiardi et al. [5]
found that the CCR5 D32 polymorphism was associated with an
increased risk of developing the aneurysmal form of CP,
particularly in patients without established atherosclerotic disease
All of these data suggest that adhesion molecules, chemokines,
Table 4. Carriage rate frequencies (%) of VEGF 936 C/T in patients with *IRF and **IAAA, and VEGF I/D in patients with/without
ureteral obstruction, conservative treatment, and deep vein thrombosis&.
Variables 936 TC+936 TT 936 CC P values OR (95% CI)
IRF 22 (26.5) 61 (73.5) 0.046 6.49 [0.82–51.54]
IAAA 1 (5.3) 18 (94.7)
II+ID DD
Ureteral obstruction 57 (83.8) 20 (58.8) 0.006 3.63 [1.42–9.28]
Absence of ureteral obstruction 11 (16.2) 14 (41.2)
II+ID DD
Conservative treatment 33 (48.5) 8 (23.5) 0.015 3.06 [1.22–7.72]
No conservative treatment 35 (51.5) 26 (76.5)
II DD+ID
Deep vein thrombosis 7 (30.4) 9 (11.7) 0.031 3.31 [1.07–10.21]
Absence of deep vein thrombosis 16 (69.6) 68 (88.3)
*Idiopathic retroperitoneal fibrosis (IRF);
**inflammatory abdominal aortic aneurysms (IAAA);
&Values are the number/total number examined (%).
OR = odds ratio; 95% CI = 95% confidence intervals.
doi:10.1371/journal.pone.0062330.t004
Figure 1. Serum VEGF levels in 17 patients with chronic
periaortitis (CP) and 11 age- and gender-matched healthy
controls (HC). VEGF tended to be higher in the CP group, but
the difference was not statistically significant (p = 0.081).
doi:10.1371/journal.pone.0062330.g001
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may play a key role in the initiation and progression of the chronic
inflammatory response associated with CP.
VEGF production may be partially subject to genetic control
[30–32]. All of the three VEGF polymorphisms evaluated in our
study have been linked to variations in plasma VEGF levels and
VEGF production by mononuclear cells [30–32]. Brenner et al.
showed that plasma VEGF levels were significantly lower in
healthy carriers of the 936T allele that in non-carriers [30], and we
found similar results in our patients with IRF. The serum levels of
VEGF were higher in the IRF patients with the CC genotype than
in those with the C/T genotype or healthy controls, but were
similar in the healthy controls and the patients with the C/T
genotype. There was no association between the three polymor-
phisms and CP, but the +936T allele was significantly more
frequent in patients with IRF than in those with IAAA. The
functional relevance of this association is still unclear; we measured
VEGF levels in IRF patients and healthy controls (no serum
samples were available from IAAA patients), and found no
significant difference between them. However, as the small
number of patients might have limited our ability to detect a
difference, larger studies are needed to address this issue. VEGF
may be relevant to the pathogenesis of both aneurysmal and non-
aneurysmal forms of CP because of its potential pro-fibrotic effects
[45,46] and its over-expression in human abdominal aortic
aneurysms [47].
We found that carriers of the I allele (II+ID) were more
susceptible to the development of ureteral obstruction and more
likely to receive conservative treatment (i.e. stent placement).
Ureteral obstruction is the most frequent complication of CP, and
involves both ureters in 50–80% of cases [48–50].
The I/D polymorphism seems to be functionally relevant. We
have shown that LPS-stimulated VEGF production by peripheral
blood mononuclear cells was higher in II homozygotes than in DD
homozygotes [33,34]. By facilitating retroperitoneal mass growth
and the fibrotic process, the angiogenic and pro-inflammatory
properties of VEGF may be responsible for this association
[45,46]. A genetic variation in VEGF production may therefore
influence susceptibility to ureteral obstruction and the need for
stent placement. Interestingly, a number of studies have shown
associations between the same VEGF polymorphisms encoding
higher VEGF production and end-stage renal disease [51] and
acute renal allograft rejection [52].
We also found that deep vein thrombosis was significantly more
frequent in the II homozygous patients. It is not entirely clear why
increased VEGF production may increase the risk of thrombosis.
CP-related thrombosis can be due to the compression of adjacent
veins by the retroperitoneal mass [50], and so higher levels of
VEGF production may increase the risk of thrombosis by
favouring retroperitoneal mass growth. Alternatively, higher
VEGF levels could facilitate the development of thrombosis by
activating endothelial cells and promoting the adhesion and
activation of platelets [53]. In this regard, it is worth noting that
high serum VEGF levels have been found in patients with
polycythemia vera and thrombotic complications [54]. These
hypotheses are not mutually exclusive.
The results of this study should be interpreted very cautiously
because the small sample sizes after sub-grouping can easily induce
a type 1 error. Further studies are required to replicate our
findings in other populations and clarify the role of VEGF in the
inflammatory events leading to vascular injury or thrombosis in
patients with CP.
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Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in
skeletal muscle. Gene Ther 18: 1166–1172.
46. Kim DH, Lee NY, Lee MH, Sohn SK (2008) Vascular endothelial growth factor
gene polymorphisms may predict the risk of acutegraft-versus-host disease
following allogeneic transplantation: preventive effect of vascular endothelial
growth factor gene on acutegraft-versus-host disease. Biol Blood Marrow
Transplant 14: 1408–1416.
47. Kaneko H, Anzai T, Takahashi T, Anzai A, Takahashi T, et al. (2011) Role of
vascular endothelial growth factor-A in development of abdominal aortic
aneurysm. Cardiovasc Res 91: 358–367.
48. Kardar AH, Kattan S, Lindstedt E, Hanash K (2002) Steroid therapy for
idiopathic retroperitoneal fibrosis: dose and duration. J Urol 168: 550–555.
49. van Bommel EF, Siemes C, Hak LE, Hak LE, van der Veer SJ, et al. (2007)
Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis
treated with prednisone. Am J Kidney Dis 49:615–625.
50. Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory
disorder. Best Practice & Research Clinical Rheum 23: 339–353.
51. Prakash S, Prasad N, Sharma RK, Faridi RM, Agrawal S (2012) Vascular
endothelial growth factor gene polymorphisms in North Indian patients with
end-stage renal disease. Cytokine 58: 261–266.
52. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, et al. (2002)
Vascular endothelial growth factor gene polymorphisms are associated with
acute renal allograft rejection. J Am Soc Nephrol 13: 260–264.
53. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, et al.
(2000) Vascular endothelial growth factor-stimulated endothelial cells promote
adhesion and activation of platelets. Blood 96: 4216–4221.
54. Cacciola RR, Di Francesco E, Giustolisi R, Cacciola E (2002) Elevated serum
vascular endothelial growth factor levels in patients with polycythemia vera and
thrombotic complications. Haematologica 87: 774–775.
TLR-4 and VEGF Polymorphisms in CP
PLOS ONE | www.plosone.org 8 May 2013 | Volume 8 | Issue 5 | e62330
